MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Intersect ENT claims reimbursement win for Propel drug-eluting sinus implant

Intersect ENT claims reimbursement win for Propel drug-eluting sinus implant

By

Intersect ENTIntersect ENT (NSDQ:XENT) said today that it won a positive coverage decision from CareFirst BlueCross BlueShield for its Propel and Propel Mini drug-eluting sinus implants.

The devices are designed to elute the anti-inflammatory steroid mometasone furoate; Menlo Park, Calif.-based Intersect won FDA approval for the original Propel implant in August 2011 and for the Propel Mini the following September. The implants are designed to dissolve into the body over time.

CareFirst BlueCross BlueShield has some 3.2 million lives under coverage in Washington, D.C., Maryland and northern Virginia, including more than 577,000 in the Federal Employees Health Program.

“We are thrilled to add CareFirst to the growing list of payors who recognize the clinical and economic value of Propel and Propel Mini in addressing the needs of chronic sinusitis patients,” president & CEO Lisa Earnhardt said in prepared remarks. “This decision reflects continued positive momentum in obtaining favorable reimbursement for Propel.”

The health insurer said it based the decision on clinical studies showing the safety and effectiveness of the Propel treatment.

“Use of a mometasone furoate-eluting sinus implant, such as Propel, is considered medically necessary in conjunction with functional endoscopic sinus surgery (FESS) or other sinus procedure,” according to CareFirst BlueCross BlueShield. “Despite the limitations of the studies, the actions of topically applied corticosteroid drugs in conjunction with FESS are known. The Propel implant is an example of a product that releases a steroid drug safely and effectively over time. Therefore the implant is considered medically necessary when used in accordance with its approved labeling.”

Intersect is also working on a pair of other drug-eluting, bioresorbable implant, 1 called Nova and another called Resolve. The company raised $103 million in an initial public offering back in June 2015.

In case you missed it

RSS From Medical Design & Outsourcing

  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. They come in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
    A new study in the Heart Rhythm Journal showed a magnetic charger for the iPhone 12 was able to deactivate a Medtronic implantable cardioverter defibrillator (ICD). The iPhone 12 has a circular array of magnets deployed around a central charging coil, making it compatible with the company’s wireless “MagSafe” accessories, according to the study published… […]
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
    Steris (NYSE:STE) announced today that it will acquire Cantel Medical (NYSE:CMD) for $4.6 billion — a major merger in the infection prevention space. The deal is expected to close by June 30, pending customary closing conditions, regulatory approvals and an OK by Cantel shareholders. News of the merger comes a month and a half after Steris closed… […]
  • How Abbott stayed two steps ahead of COVID-19
    Developing a fast COVID-19 that resembled a pregnancy test and building two factories to boost productions — those were but two of the quick-thinking actions that Abbott (NYSE:ABT) officials took in the early months of a deadly coronavirus pandemic. Abbott began tracking the virus in China at the end of 2019 and into early 2020. By February,… […]
  • BREAKING: Big medtech suspends political contributions in wake of Electoral College vote
    Just as they lined up to condemn last week’s attack on the U.S. Capitol, major medtech companies are suspending political contributions because of 147 federal lawmakers’ refusal to acknowledge the Electoral College win by President-elect Joe Biden and Vice President-elect Kamala Harris. Boston Scientific announced on Sunday that it has chosen to temporarily suspend its… […]
  • Neurofeedback could help prostheses feel lighter: Here’s how
    Researchers at ETH Zurich have developed a prosthesis system that connects to the body’s nervous system to help amputees perceive a prosthetic weight as lower. The prosthesis system provides feedback to the wearer using electrodes implanted in the thigh that are connected to the leg nerves. Information from the tactile sensors under the sole of… […]